GLO1 and breast carcinoma: Of interest, GLO1 inhibitors have been shown to reverse the sensitivity of tamoxifen-resistant breast cancer cells, revealing that GLO1 may be a biomarker for predicting the efficacy of endocrine therapies and a target for overcoming treatment resistance (158).